332 related articles for article (PubMed ID: 11731950)
1. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication.
Pomerantz RJ
Clin Infect Dis; 2002 Jan; 34(1):91-7. PubMed ID: 11731950
[TBL] [Abstract][Full Text] [Related]
2. Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1.
Pomerantz RJ
HIV Clin Trials; 2003; 4(2):137-43. PubMed ID: 12671782
[TBL] [Abstract][Full Text] [Related]
3. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy.
Saksena NK; Potter SJ
AIDS Rev; 2003; 5(1):3-18. PubMed ID: 12875103
[TBL] [Abstract][Full Text] [Related]
4. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.
Kulkosky J; Nunnari G; Otero M; Calarota S; Dornadula G; Zhang H; Malin A; Sullivan J; Xu Y; DeSimone J; Babinchak T; Stern J; Cavert W; Haase A; Pomerantz RJ
J Infect Dis; 2002 Nov; 186(10):1403-11. PubMed ID: 12404155
[TBL] [Abstract][Full Text] [Related]
5. Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy.
Kulkosky J; Pomerantz RJ
Clin Infect Dis; 2002 Dec; 35(12):1520-6. PubMed ID: 12471572
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups.
Dornadula G; Nunnari G; Vanella M; Roman J; Babinchak T; DeSimone J; Stern J; Braffman M; Zhang H; Pomerantz RJ
J Infect Dis; 2001 Jun; 183(11):1682-7. PubMed ID: 11343220
[TBL] [Abstract][Full Text] [Related]
7. Hidden HIV reservoirs: will eradication of the virus be possible?
Gomez E
Newsline People AIDS Coalit N Y; 1998 Mar; ():18-9. PubMed ID: 11367451
[TBL] [Abstract][Full Text] [Related]
8. Eliminating HIV-1 reservoirs.
Pomerantz RJ
Curr Opin Investig Drugs; 2002 Aug; 3(8):1133-7. PubMed ID: 12211403
[TBL] [Abstract][Full Text] [Related]
9. A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation.
Pippi F
Med Hypotheses; 2008; 70(2):291-3. PubMed ID: 17681707
[TBL] [Abstract][Full Text] [Related]
10. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
11. Establishment of latent HIV-1 infection of resting CD4(+) T lymphocytes does not require inactivation of Vpr.
Shen A; Siliciano JD; Pierson TC; Buck CB; Siliciano RF
Virology; 2000 Dec; 278(1):227-33. PubMed ID: 11112497
[TBL] [Abstract][Full Text] [Related]
12. Ludwik Hirszfeld Memorial Lecture: HIV-1 reservoirs: major molecular obstacles to viral eradication.
Pomerantz RJ
Arch Immunol Ther Exp (Warsz); 2004; 52(5):297-306. PubMed ID: 15507870
[TBL] [Abstract][Full Text] [Related]
13. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes.
Redel L; Le Douce V; Cherrier T; Marban C; Janossy A; Aunis D; Van Lint C; Rohr O; Schwartz C
J Leukoc Biol; 2010 Apr; 87(4):575-88. PubMed ID: 19801499
[TBL] [Abstract][Full Text] [Related]
15. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy.
Ikeda T; Shibata J; Yoshimura K; Koito A; Matsushita S
J Infect Dis; 2007 Mar; 195(5):716-25. PubMed ID: 17262715
[TBL] [Abstract][Full Text] [Related]
16. In vitro reactivation of human immunodeficiency virus 1 from latently infected, resting CD4+ T cells after bacterial stimulation.
Moriuchi H; Moriuchi M; Mizell SB; Ehler LA; Fauci AS
J Infect Dis; 2000 Jun; 181(6):2041-4. PubMed ID: 10837189
[TBL] [Abstract][Full Text] [Related]
17. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.
Chun TW; Davey RT; Ostrowski M; Shawn Justement J; Engel D; Mullins JI; Fauci AS
Nat Med; 2000 Jul; 6(7):757-61. PubMed ID: 10888923
[TBL] [Abstract][Full Text] [Related]
18. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes.
Huang J; Wang F; Argyris E; Chen K; Liang Z; Tian H; Huang W; Squires K; Verlinghieri G; Zhang H
Nat Med; 2007 Oct; 13(10):1241-7. PubMed ID: 17906637
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.
Routy JP; Tremblay CL; Angel JB; Trottier B; Rouleau D; Baril JG; Harris M; Trottier S; Singer J; Chomont N; Sékaly RP; Boulassel MR
HIV Med; 2012 May; 13(5):291-6. PubMed ID: 22276680
[TBL] [Abstract][Full Text] [Related]
20. Latency: the hidden HIV-1 challenge.
Marcello A
Retrovirology; 2006 Jan; 3():7. PubMed ID: 16412247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
